Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
AffiliationCancer Research Campaign Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. email@example.com
MetadataShow full item record
AbstractPURPOSE: To establish whether temozolomide is more effective against A375M human melanoma xenografts if given every 4 h rather than every 24 h, in order to exploit depletion of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (ATase) by prior doses of the drug. METHODS: ATase depletion in A375M human melanoma xenografts was determined over 24 h after a single dose of temozolomide. The effect of different drug schedules (all of total dose 500 mg/kg) in delaying the growth of the xenografts was tested, and ATase depletion and DNA methylation damage assessed in tumour and normal tissue. RESULTS: Maximal depletion of ATase in tumour, to 2.52 +/- 0.23% of pretreatment levels, occurred 4-8 h after a single 100 mg/kg i.p. dose of temozolomide, with 23.0% recovery of protein levels at 24 h. Scheduling of temozolomide every 4 h increased tumour growth delay (33.6 +/- 1.39 days with temozolomide 100 mg/kg 4-hourly x versus 23.2 +/- 1.43 days with temozolomide 100 mg/kg once daily x 5; P < 0.0001) at the expense of increased toxicity (17.4 +/- 1.55% animal weight loss versus 10.6 +/- 1.27%. respectively). Temozolomide every 4 h did not increase ATase depletion compared with the 5-day schedule, but resulted in greater DNA 06-guanine methylation (29.0% more in tumour, 20.8% in liver and 56.0% in brain, comparing areas under the methylation-time curve). CONCLUSIONS: The 4-hourly schedule of temozolomide delayed tumour growth significantly more than the once-daily and 12-hourly schedules, probably as a result of greater DNA damage inflicted, but also increased toxicity. It remains to be seen if this regimen confers a net benefit over the standard schedule.
CitationFour-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts. 2000, 45 (1):15-20 Cancer Chemother. Pharmacol.
JournalCancer Chemotherapy and Pharmacology
- O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
- Authors: Middleton MR, Kelly J, Thatcher N, Donnelly DJ, McElhinney RS, McMurry TB, McCormick JE, Margison GP
- Issue date: 2000 Jan 15
- Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
- Authors: Middleton MR, Thatcher N, McMurry TB, McElhinney RS, Donnelly DJ, Margison GP
- Issue date: 2002 Aug 10
- Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model.
- Authors: Wedge SR, Porteous JK, Newlands ES
- Issue date: 1997
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
- Authors: Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK
- Issue date: 2003 Apr 7
- Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
- Authors: Lee SM, Thatcher N, Crowther D, Margison GP
- Issue date: 1994 Mar